ImmunoGen Stock Price

0.18 (3.1%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
ImmunoGen Inc IMGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.18 3.1% 5.995 13:04:26
Open Price Low Price High Price Close Price Previous Close
5.82 5.72 6.24 5.815
Bid Price Ask Price Spread News
5.99 6.00 0.01 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
9,813 1,801,062 $ 6.08 $ 10,949,998 2,610,110 1.95 - 7.07
Last Trade Time Type Quantity Stock Price Currency
13:04:27 200 $ 5.995 USD

ImmunoGen Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.12B 187.53M 168.63M $ 82.27M $ -63.88M -0.70 -14.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 1.20%

more financials information »

ImmunoGen News

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IMGN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week5.356.245.245.601,432,9600.64512.06%
1 Month6.246.515.185.822,135,620-0.245-3.93%
3 Months3.736.513.435.082,630,1402.2760.72%
6 Months4.756.513.384.682,270,6601.2526.21%
1 Year3.577.071.954.582,701,0882.4367.93%
3 Years6.2113.411.655.602,621,824-0.215-3.46%
5 Years12.9214.101.515.462,384,460-6.93-53.6%

ImmunoGen Description

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201204 18:19:30